Editorial

DOI: 10.4244/EIJ-E-24-00046

Phoenix rising: a credible signal for CABG from ISCHEMIA?

John A. Bittl, MD

When the writing committee (WC) for the U.S. coronary revascularisation guideline downgraded the recommendation for using coronary artery bypass graft (CABG) surgery to improve survival in patients with multivessel chronic coronary disease (CCD) from Class 1 (“should be done”) in 20111 to Class 2b (“may be reasonable”) in 20212 and placed it on par with the other 2b recommendation (“is uncertain”) for percutaneous coronary intervention (PCI)2, surgeons cried foul3. The original CABG recommendation1 was based on older studies and a meta-analysis from 19944, which suggested that study subjects with three-vessel coronary artery disease had better survival 5 years after CABG than they would have had if they had received medical therapy (MT) alone. The 2011 WC knew that MT in the older trials consisted of aspirin in 26% and beta blockers in 66% of subjects4 but rationalised that it was based on the best evidence at the time. As evidence grew and the concept of guideline-directed medical therapy (GDMT) emerged, the 2021 WC concluded that MT in older studies amounted to almost nothing....

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 20
Oct 21, 2024
Volume 20 Number 20
View full issue


Key metrics

Trending articles
76.3

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
56.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
45.35

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
28.25

Clinical research

10.4244/EIJ-D-19-01006 Aug 7, 2020
Coronary collaterals and myocardial viability in patients with chronic total occlusions
Schumacher S et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved